SEC Form 4 · accession 0001140361-15-012559
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Mar 16, 2015
Accepted (ET)
Mar 18, 2015 · 8:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Mar 16, 2015 | S | 1,000 | $123.477 | D | 35,258 | I | Shares held by Bienaime Family Trust |
| Common StockF1,F4,F3 | Mar 17, 2015 | S | 1,000 | $124.866 | D | 34,258 | I | Shares held by Bienaime Family Trust |
| Common Stock | holding | — | — | — | 254,757 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed March 2, 2015.
- F2The price in column 4 is an average weighted price. The price actually received ranged from $121.98 to $124.52. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.
- F3The reporting person an his spouse act as trustees for the Bienaime Family Trust
- F4The price in column 4 is an average weighted price. The price actually received ranged from $123.74 to $126.26. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.